Mission Therapeutics Ltd of the UK has raised £20 million in a series B financing round to support the development of enzyme inhibitors that are thought to have the potential of targeting difficult-to-treat cancers. The enzymes are deubiquitylating enzymes involved in the DNA damage response.
